Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914322476> ?p ?o ?g. }
- W2914322476 endingPage "239" @default.
- W2914322476 startingPage "231" @default.
- W2914322476 abstract "BackgroundAcute myeloid leukemia (AML) remains one of the most lethal, rarely cured cancers, despite decades of active development of AML therapeutics. Currently, the 5-year survival of AML patients is about 30% and for elderly patients, the rate drops to <10%. About 30% of AML patients harbor an activating mutation in the tyrosine kinase domain (TKD) of Fms-Like Tyrosine kinase 3 (FLT3) or a FLT3 internal tandem duplication (FLT3-ITD). Inhibitors of FLT3, such as Rydapt that was recently approved by the FDA, have shown good initial response but patients often relapse due to secondary mutations in the FLT3 TKD, like D835Y and F691 L mutations.MethodsAlkynyl aminoisoquinoline and naphthyridine compounds were synthesized via Sonogashira coupling. The compounds were evaluated for their in vitro and in vivo effects on leukemia growth.FindingsThe compounds inhibited FLT3 kinase activity at low nanomolar concentrations. The lead compound, HSN431, also inhibited Src kinase activity. The compounds potently inhibited the viability of MV4–11 and MOLM-14 AML cells with IC50 values <1 nM. Furthermore, the viability of drug-resistant AML cells harboring the D835Y and F691 L mutations were potently inhibited. In vivo efficacy studies in mice demonstrated that the compounds could drastically reduce AML proliferation in mice.InterpretationCompounds that inhibit FLT3 and downstream targets like Src (for example HSN431) are good leads for development as anti-AML agents.FundPurdue University, Purdue Institute for Drug Discovery (PIDD), Purdue University Center for Cancer Research, Elks Foundation and NIH P30 CA023168." @default.
- W2914322476 created "2019-02-21" @default.
- W2914322476 creator A5008580551 @default.
- W2914322476 creator A5025132222 @default.
- W2914322476 creator A5031465905 @default.
- W2914322476 creator A5036344555 @default.
- W2914322476 creator A5037299132 @default.
- W2914322476 creator A5054423927 @default.
- W2914322476 creator A5059885553 @default.
- W2914322476 creator A5062792789 @default.
- W2914322476 creator A5065878482 @default.
- W2914322476 creator A5067229838 @default.
- W2914322476 creator A5070535778 @default.
- W2914322476 date "2019-02-01" @default.
- W2914322476 modified "2023-10-16" @default.
- W2914322476 title "Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice" @default.
- W2914322476 cites W1503281372 @default.
- W2914322476 cites W1504864970 @default.
- W2914322476 cites W1592701464 @default.
- W2914322476 cites W1984209370 @default.
- W2914322476 cites W1984712646 @default.
- W2914322476 cites W1996092483 @default.
- W2914322476 cites W2005400731 @default.
- W2914322476 cites W2011187792 @default.
- W2914322476 cites W2016150193 @default.
- W2914322476 cites W2017107901 @default.
- W2914322476 cites W2018074634 @default.
- W2914322476 cites W2030791837 @default.
- W2914322476 cites W2033043158 @default.
- W2914322476 cites W2036049148 @default.
- W2914322476 cites W2041027929 @default.
- W2914322476 cites W2041308494 @default.
- W2914322476 cites W2045809294 @default.
- W2914322476 cites W2047406713 @default.
- W2914322476 cites W2053167745 @default.
- W2914322476 cites W2064051300 @default.
- W2914322476 cites W2064901496 @default.
- W2914322476 cites W2080109272 @default.
- W2914322476 cites W2082117339 @default.
- W2914322476 cites W2086626683 @default.
- W2914322476 cites W2096340973 @default.
- W2914322476 cites W2111486257 @default.
- W2914322476 cites W2114164056 @default.
- W2914322476 cites W2114242622 @default.
- W2914322476 cites W2116858301 @default.
- W2914322476 cites W2130008241 @default.
- W2914322476 cites W2130864403 @default.
- W2914322476 cites W2138617860 @default.
- W2914322476 cites W2143854006 @default.
- W2914322476 cites W2144169031 @default.
- W2914322476 cites W2151222524 @default.
- W2914322476 cites W2153552578 @default.
- W2914322476 cites W2160140526 @default.
- W2914322476 cites W2163288750 @default.
- W2914322476 cites W2288260164 @default.
- W2914322476 cites W2295395729 @default.
- W2914322476 cites W2313576573 @default.
- W2914322476 cites W2330829715 @default.
- W2914322476 cites W2461928138 @default.
- W2914322476 cites W2587696209 @default.
- W2914322476 cites W2606036674 @default.
- W2914322476 cites W2613443539 @default.
- W2914322476 cites W2615038909 @default.
- W2914322476 cites W2620184199 @default.
- W2914322476 cites W2620653306 @default.
- W2914322476 cites W2715749014 @default.
- W2914322476 cites W2754504728 @default.
- W2914322476 cites W2773242491 @default.
- W2914322476 cites W2794836336 @default.
- W2914322476 cites W4231346141 @default.
- W2914322476 cites W4254125104 @default.
- W2914322476 doi "https://doi.org/10.1016/j.ebiom.2019.01.012" @default.
- W2914322476 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6413339" @default.
- W2914322476 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30686755" @default.
- W2914322476 hasPublicationYear "2019" @default.
- W2914322476 type Work @default.
- W2914322476 sameAs 2914322476 @default.
- W2914322476 citedByCount "8" @default.
- W2914322476 countsByYear W29143224762020 @default.
- W2914322476 countsByYear W29143224762021 @default.
- W2914322476 countsByYear W29143224762022 @default.
- W2914322476 countsByYear W29143224762023 @default.
- W2914322476 crossrefType "journal-article" @default.
- W2914322476 hasAuthorship W2914322476A5008580551 @default.
- W2914322476 hasAuthorship W2914322476A5025132222 @default.
- W2914322476 hasAuthorship W2914322476A5031465905 @default.
- W2914322476 hasAuthorship W2914322476A5036344555 @default.
- W2914322476 hasAuthorship W2914322476A5037299132 @default.
- W2914322476 hasAuthorship W2914322476A5054423927 @default.
- W2914322476 hasAuthorship W2914322476A5059885553 @default.
- W2914322476 hasAuthorship W2914322476A5062792789 @default.
- W2914322476 hasAuthorship W2914322476A5065878482 @default.
- W2914322476 hasAuthorship W2914322476A5067229838 @default.
- W2914322476 hasAuthorship W2914322476A5070535778 @default.
- W2914322476 hasBestOaLocation W29143224761 @default.
- W2914322476 hasConcept C104317684 @default.
- W2914322476 hasConcept C126322002 @default.
- W2914322476 hasConcept C150903083 @default.